Edition:
United Kingdom

OpGen Inc (OPGN.OQ)

OPGN.OQ on NASDAQ Stock Exchange Capital Market

1.93USD
7:02pm GMT
Change (% chg)

$0.08 (+4.32%)
Prev Close
$1.85
Open
$1.84
Day's High
$1.94
Day's Low
$1.84
Volume
11,735
Avg. Vol
48,310
52-wk High
$31.25
52-wk Low
$1.80

Chart for

About

OpGen, Inc. (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening... (more)

Overall

Beta: --
Market Cap(Mil.): $15.20
Shares Outstanding(Mil.): 51.56
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-OpGen Says ‍Entered Agreement To Use Thermo Fisher's Real-Time PCR Technology In Co's New Acuitas Tests​

* OPGEN INC - ‍ENTERED GLOBAL SUPPLY AGREEMENT TO USE THERMO FISHER SCIENTIFIC'S REAL-TIME PCR TECHNOLOGY IN COMPANY'S ACUITAS AMR GENE PANEL TESTS​

13 Feb 2018

BRIEF-Empery Asset Management Lp Reports 9.38 pct Passive Stake In Opgen Inc As Of Feb 1

* EMPERY ASSET MANAGEMENT, LP REPORTS 9.38 PERCENT PASSIVE STAKE IN OPGEN INC AS OF FEBRUARY 1, 2018 - SEC FILING‍​ Source text - (http://bit.ly/2FUhgjF) Further company coverage:

08 Feb 2018

BRIEF-Opgen Regains Compliance With Nasdaq Listing Requirements

* OPGEN REGAINS COMPLIANCE WITH NASDAQ LISTING REQUIREMENTS Source text for Eikon: Further company coverage:

05 Feb 2018

BRIEF-OpGen ‍Will Implement 1-For-25 Reverse Stock Split Of Common Stock​

* OPGEN INC - ‍WILL IMPLEMENT A 1-FOR-25 REVERSE STOCK SPLIT OF ITS COMMON STOCK​ Source text for Eikon: Further company coverage:

17 Jan 2018

BRIEF-Opgen reports 2017 third quarter financial results

* Opgen reports 2017 third quarter financial results and provides business update

07 Nov 2017

Earnings vs. Estimates